GENE GUIDE

SLC6A1-Related Syndrome

This guide is not meant to take the place of medical advice. Please consult with your doctor about your genetic results and health care choices. This Gene Guide was last updated on 2024. As new information comes to light with new research we will update this page. You may find it helpful to share this guide with friends and family members or doctors and teachers of the person who has SLC6A1-Related Syndrome.
a doctor sees a patient

SLC6A1-related syndrome happens when there are changes to the SLC6A1 gene. These changes can keep the gene from working as it should.

Key Role

The SLC6A1 gene plays a key role in communication between brain cells.

Symptoms

Because the SLC6A1 gene is important for brain activity, many people who have SLC6A1-related syndrome have:

  • Developmental delay
  • Intellectual disability
  • Speech delay
  • Seizures
  • Behavioral issues, including attention-deficit/hyperactivity disorder (ADHD), aggression, and features of autism
  • Movement issues

SLC6A1-related syndrome is a genetic condition, which means that it is caused by variants in genes. Our genes contain the instructions, or code, that tell our cells how to grow, develop, and work. Every child gets two copies of the SLC6A1 gene: one copy from their mother’s egg, and one copy from their father’s sperm. In most cases, parents pass on exact copies of the gene to their child. But the process of creating the egg or sperm is not perfect. A change in the genetic code can lead to physical issues, developmental issues, or both.

Sometimes a spontaneous variant happens in the sperm, egg or after fertilization. When a brand new genetic variant happens in the genetic code is called a ‘de novo’ genetic variant. The child is usually the first in the family to have the genetic variant.

De novo variants can take place in any gene. We all have some de novo variants, most of which don’t affect our health. But because SLC6A1 plays a key role in development, de novo variants in this gene can have a meaningful effect.

Research shows that SLC6A1-related syndrome is often the result of a de novo variant in SLC6A1. Many parents who have had their genes tested do not have the SLC6A1 genetic variant found in their child who has the syndrome. In some cases, SLC6A1-related syndrome happens because the genetic variant was passed down from a parent.

Autosomal dominant conditions

SLC6A1-related syndrome is an autosomal dominant genetic condition. This means that when a person has the one damaging variant in SLC6A1 they will likely have symptoms of SLC6A1-related syndrome. For someone with an autosomal dominant genetic syndrome, every time they have a child there is a 50 percent chance they pass on the same genetic variant and a 50 percent chance they do not pass on the same genetic variant.

Autosomal Dominant Genetic Syndrome

GENE / gene
GENE / gene
Genetic variant that happens in sperm or egg, or after fertilization
GENE / gene
Child with de novo genetic variant
gene / gene
Non-carrier child
gene / gene
Non-carrier child

No parent causes their child’s SLC6A1-related syndrome. We know this because no parent has any control over the gene changes that they do or do not pass on to their children. Please keep in mind that nothing a parent does before or during the pregnancy causes this to happen. The gene change takes place on its own and cannot be predicted or stopped.

Each family is different. A geneticist or genetic counselor can give you advice on the chance that this will happen again in your family.

The risk of having another child who has SLC6A1-related syndrome depends on the genes of both birth parents.

  • If neither birth parent has the same gene change found in their child, the chance of having another child who has the syndrome is on average 1 percent. This 1 percent chance is higher than the chance of the general population. The increase in risk is due to the very unlikely chance that more of the mother’s egg cells or the father’s sperm cells carry the same change in the gene.
  • If one birth parent has the same gene change found in their child, the chance of having another child who has the syndrome is 50 percent.

For a symptom-free sibling, a brother or sister, of someone who has SLC6A1-related syndrome, the risk of having a child who has the syndrome depends on the symptom-free sibling’s genes and their parents’ genes.

  • If neither parent has the same gene change found in their child who has the syndrome, the symptom-free sibling has a nearly 0 percent chance of having a child who has SLC6A1-related syndrome.
  • If one birth parent has the same gene change found in their child who has the syndrome, the symptom-free sibling has a small chance of also having the same gene change. If the symptom- free sibling has the same gene change as their sibling who has the syndrome, the symptom-free sibling’s chance of having a child who has SLC6A1-related syndrome is 50 percent.

For a person who has SLC6A1-related syndrome, the risk of having a child who has the syndrome is about 50 percent.

As of 2024, at least 209 people with SLC6A1-related syndrome have been identified in a medical clinic.

People who have SLC6A1-related syndrome do not look different.

Scientists and doctors have only just begun to study SLC6A1-related syndrome. At this point, there are no medicines designed to treat the syndrome. A genetic diagnosis can help people decide on the best way to track the condition and manage therapies. Doctors can refer people to specialists for:

  • Physical exams and brain studies
  • Genetics consults
  • Development and behavior studies
  • Other issues, as needed

A developmental pediatrician, neurologist, or psychologist can follow progress over time and can help:

  • Suggest the right therapies. This can include physical, occupational, speech, or behavioral therapy.
  • Guide individualized education plans (IEPs).

Specialists advise that therapies for SLC6A1-related syndrome should begin as early as possible, ideally before a child begins school.

If seizures happen, consult a neurologist. There are many types of seizures, and not all types are easy to spot. To learn more, you can refer to resources such as the Epilepsy Foundation’s website: epilepsy.com/…t-is-epilepsy/seizure-types

This section includes a summary of information from major published articles and the Simons Searchlight quarterly registry report. It highlights how many people have different symptoms. To learn more about the articles, see the Sources and References section of this guide.

Some people inherit an SLC6A1 variant from a parent who may or may not have medical features. About 20 out of 118 people with SLC6A1-related syndrome inherited the variant from a parent. Siblings and first-degree relatives carrying the variant usually have variable symptoms that are milder than the symptoms of the person with SLC6A1-related syndrome.

Speech and Learning

Many people with SLC6A1-related syndrome had developmental delay or intellectual disability. Most people had moderate to mild intellectual disability. Eleven people with average IQ were described in the research literature, and some people had learning disorders and/or epilepsy. Developmental delay was often reported by parents before seizure onset. Some people had developmental regression around the age of 3 years old.

  • 98 out of 119 people had developmental delay or intellectual disability (82 percent)
  • 15 out of 119 people had developmental regression (13 percent)

Behavior

Behavioral disorders occurred in about 1 out of 3 people with SLC6A1-related syndrome. About one-half of people had autism or features of autism, and a few had attention-deficit/hyperactivity disorder (ADHD).

  • 41 out of 119 people had behavioral disorders (35 percent)
  • 64 out of 119 people had autism or features of autism (54 percent)
  • 20 out of 119 people had ADHD (17 percent)
35%
41 out of 119 people had behavioral disorders.
54%
64 out of 119 people had autism or features of autism.
17%
20 out of 119 people had ADHD.

Brain

Most people with SLC6A1-related syndrome had seizures. Seizure types included absences with or without eyelid myoclonia, atonic, myoclonic, tonic–clonic (grand mal), and focal seizures. People often had more than one seizure type. In a study of adults with SLC6A1-related syndrome, 7 out of 11 adults had seizures that were refractory.

  • 169 out of 204 people had seizures (83 percent)
  • 94 out of 116 people had absences with or without eyelid myoclonia seizures (81 percent)
  • 70 out of 116 people had atonic seizures (60 percent)
  • 58 out of 116 people had myoclonic seizures (50 percent)
  • 22 out of 116 people had tonic–clonic seizures (19 percent)
  • 9 out of 116 people had focal seizures (8 percent)
Human head showing brain outline
83%
169 out of 204 people had seizures.
81%
94 out of 116 people had absences with or without eyelid myoclonia seizures.
60%
70 out of 116 people had atonic seizures.
50%
58 out of 116 people had myoclonic seizures.
19%
22 out of 116 people had tonic–clonic seizures.
8%
9 out of 116 people had focal seizures.

Other findings

Some people with SLC6A1-related syndrome had sleep difficulties, lower than average muscle tone, and movement disorders. The most common movement disorders were tremors and ataxia.

  • 16 out of 24 people had sleep issues (67 percent)
  • 56 out of 83 people had lower than average muscle tone (68 percent)
  • 31 out of 83 people had movement disorders (37 percent)

Where can I find support and resources?

SLC6A1 Connect

SLC6A1 Connect is a patient advocacy group dedicated to improving the lives of children and families affected by SLC6A1.

Geisinger Developmental Brain Disorder Gene Database

SLC6A1 Gene Reviews

Simons Searchlight

Simons Searchlight is an online international research program, building an ever growing natural history database, biorepository, and resource network of over 175 rare genetic neurodevelopmental disorders. By joining their community and sharing your experiences, you contribute to a growing database used by scientists worldwide to advance the understanding of your genetic condition. Through online surveys and optional blood sample collection, they gather valuable information to improve lives and drive scientific progress. Families like yours are the key to making meaningful progress. To register for Simons Searchlight, go to the Simons Searchlight website at www.simonssearchlight.org and click “Join Us.”

Sources and References

  • Goodspeed, K., Demarest, S., Johannesen, K., Kang, J., Lal, D., & Angione, K., SLC6A1-related neurodevelopmental disorder. 2023 Feb 9. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK589173/
  • Johannesen, K. M., Nielsen, J., Sabers, A., Isidor, B., Kattentidt-Mouravieva, A. A., Zieglgänsberger, D., Heidlebaugh, A. R., Oetjens, K. F., Vidal, A. A., … & Rubboli, G. (2023). The phenotypic presentation of adult individuals with SLC6A1-related neurodevelopmental disorders. Frontiers in Neuroscience, 17, 1216653. https://pubmed.ncbi.nlm.nih.gov/37662110/
  • Kassabian, B., Fenger, C. D., Willems, M., Aledo-Serrano, A., Linnankivi, T., McDonnell, P. P., Lusk, L., Jepsen, B. S., Bayat, M., … & Rubboli, G. (2023). Intrafamilial variability in SLC6A1-related neurodevelopmental disorders. Frontiers in Neuroscience, 17, 1219262. https://pubmed.ncbi.nlm.nih.gov/37502687/
  • Simons Searchlight registry update April 2024. https://cdn.simonssearchlight.org/wp-content/uploads/2024/04/16044447/SCN2A-23Q4-24Q1.pdf
  • Stefanski, A., Pérez-Palma, E., Brünger, T., Montanucci, L., Gati, C., Klöckner, C., Johannesen, K. M., Goodspeed, K., Macnee, M., … & Lal, D. (2023). SLC6A1 variant pathogenicity, molecular function and phenotype: A genetic and clinical analysis. Brain, 146(12), 5198-5208. https://pubmed.ncbi.nlm.nih.gov/37647852/
  • Trivisano, M., Butera, A., Quintavalle, C., De Dominicis, A., Calabrese, C., Cappelletti, S., Vigevano, F., Novelli, A., & Specchio, N. (2023). Insights into cognitive and behavioral comorbidities of SLC6A1-related epilepsy: Five new cases and literature review. Frontiers in Neuroscience, 17, 1215684. https://pubmed.ncbi.nlm.nih.gov/37700749/

Stay connected with Simons Searchlight

Join our newsletter to receive updates